利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.03 秒)

    STICK PACK WITH APPLICATOR
    2.
    发明申请
    STICK PACK WITH APPLICATOR 审中-公开
    贴纸包装

    公开(公告)号：US20140114262A1

    公开(公告)日：2014-04-24

    申请号：US14116007

    申请日：2012-04-30

    申请人： Sébastien Lucien Fily

    发明人： Sébastien Lucien Fily

    IPC分类号： A61M35/00

    CPC分类号： A61M35/003 ,  A45D34/04 ,  A45D37/00 ,  A45D2200/1018 ,  A61M35/006

    摘要： Stick pack (10) for a liquid, cream or gel-type product comprising a tubular sachet (12) with a first end (14) and a second end (16); a first portion (13) close to the first end (14) being filled with liquid, cream or gel-type product; a second portion (15); an applicator insert (20) between said first end (14) and said second end (16), said applicator insert (20) being sealed to the tubular sachet (12) such that no product can pass between the wall of the tubular sachet (12) and the applicator insert (20), said applicator insert (20) having a passage (22) for the product.

    摘要翻译： 用于包含具有第一端（14）和第二端（16）的管状小袋（12）的液体，奶油或凝胶型产品的棒状包装（10） 靠近第一端（14）的第一部分（13）充满液体，奶油或凝胶型产品; 第二部分（15）; 在所述第一端（14）和所述第二端（16）之间的施加器插入件（20），所述施用器插入件（20）被密封到所述管状小袋（12），使得没有产品可以在所述管状小袋的壁 12）和涂抹器插入件（20），所述涂抹器插入件（20）具有用于产品的通道（22）。

    Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside
    4.
    发明授权
    Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside 有权
    用于制备含有十七烷基苷和末端内酯的积雪草提取物的方法

    公开(公告)号：US08163706B2

    公开(公告)日：2012-04-24

    申请号：US12009696

    申请日：2008-01-22

    申请人： Alain Loiseau ,  Gérard Sene ,  Eric Theron

    发明人： Alain Loiseau ,  Gérard Sene ,  Eric Theron

    IPC分类号： A01N45/00

    CPC分类号： A61K8/97 ,  A61K36/23 ,  A61Q19/00 ,  A61Q19/08

    摘要： The invention concerns an extract of Centella asiatica comprising more than 75 wt. % of a mixture of madecassoside, terminoloside and asiaticoside, relative to the extract total weight, an extract of Centella asiatica comprising more than 95 wt. % of a mixture of madecassoside and terminoloside relative to the extract total weight and their use for regulating inflammatory mechanisms.

    摘要翻译： 本发明涉及积雪草提取物，其包含超过75wt。 相对于提取物总重量的十五烷基苷，末端内切酶和积雪草苷的混合物的％，积雪草积聚物的提取物，其包含大于95wt。 相对于提取物总重量，十五烷醇和末端酯的混合物的百分比以及它们用于调节炎症机制的用途。

    Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate
    5.
    发明申请
    Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate 审中-公开
    不含泡腾形式的萘普生钠，包括： 碳酸氢钠

    公开(公告)号：US20070134317A1

    公开(公告)日：2007-06-14

    申请号：US10577197

    申请日：2004-10-29

    申请人： Peter Gruber ,  Martin Siegmund

    发明人： Peter Gruber ,  Martin Siegmund

    IPC分类号： A61K9/20

    CPC分类号： A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K31/192

    摘要： A non effervescent tablet of sodium naproxen, comprising a tablet core and, if desired, a sugar or film coat, wherein the tablet core, based on the weight of the tablet core, consists of 30 to 99% by weight sodium naproxen and 70 to 1% by weight auxiliary agent component comprising at least one basic auxiliary agenL possesses a sufficient hardness, is comparatively small and leads to a particularly rapid increase in blood level and thereby to an accelerated onset of analgesic effect.

    摘要翻译： 萘普生钠的非泡腾片剂，其包含片芯，如果需要，包含糖或薄膜包衣，其中片芯基于片芯的重量由30-99重量％的萘普生钠和70至 包含至少一种碱性辅助剂的1重量％助剂组分具有足够的硬度，相对较小，导致血液水平特别快速的增加，从而加速止痛效果。

    Combination of a PI3K-inhibitor with an androgen receptor antagonist
    8.
    发明授权
    Combination of a PI3K-inhibitor with an androgen receptor antagonist 有权

    公开(公告)号：US11185549B2

    公开(公告)日：2021-11-30

    申请号：US16624156

    申请日：2018-06-21

    申请人： BAYER CONSUMER CARE AG ,  BAYER PHARMA AKTIENGESELLSCHAFT

    发明人： Bernard Haendler

    IPC分类号： A61K31/5375 ,  A61K31/4164 ,  A61K31/415 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/4152 ,  A61K31/4155 ,  A61K45/06

    摘要： The present invention relates to: • combinations of: * a component A: which is a PI3K kinase inhibitor, such as copanlisib, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same, for example; * a component B: which is an androgen receptor antagonist, such as darolutamide or enzalutamide for example; and, optionally, * one or more pharmaceutical agents C; in which optionally either or both of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially; • use of such combinations: * in the treatment or prophylaxis of a cancer, particularly prostate cancer, or * for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly prostate cancer; • methods of treatment or prophylaxis of a cancer, particularly prostate cancer, in a subject, comprising administering to said subject a therapeutically effective amount of such a combination; • compositions containing such a combination, together with pharmaceutically acceptable ingredients; and • kits comprising such a combination.